Arbutus Biopharma Corporation (ABUS)
| Market Cap | 596.35M |
| Revenue (ttm) | 12.99M |
| Net Income (ttm) | -74.39M |
| Shares Out | 188.72M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 651,566 |
| Open | 3.250 |
| Previous Close | 3.250 |
| Day's Range | 3.140 - 3.260 |
| 52-Week Range | 1.690 - 3.640 |
| Beta | 1.98 |
| Analysts | Strong Buy |
| Price Target | 4.33 (+37.03%) |
| Earnings Date | Aug 1, 2024 |
About ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, ... [Read more]
Financial Performance
In 2023, ABUS's revenue was $18.14 million, a decrease of -53.51% compared to the previous year's $39.02 million. Losses were -$72.85 million, 4.89% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ABUS stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 37.03% from the latest price.
News
Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress
Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were ...
Arbutus Distributors Ltd. News Release
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- Mr. Peter Bull and Arbutus Distributors Ltd. (“Arbutus”), a private investment and holding company controlled by Mr. Bull, announced toda...
Arbutus to Participate in Jefferies Global Healthcare Conference
WARMINSTER, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func...
Arbutus to Present Imdusiran Data at EASL Congress 2024
WARMINSTER, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbut...
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a func...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolog...
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fu...
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a fun...
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline
Arbutus to Present at Jefferies London Healthcare Conference
WARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-spec...
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), ...
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical com...
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virolo...